Pharmacotherapy for Alzheimer's disease

2002

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The intensity of interest in therapy for Alzheimer's disease (AD) has accelerated with each passing year. The nature of the effects of cholinesterase inhibitors has been refined with the publication of several studies that have examined long-term therapy as well as different aspects of the symptomatology of AD. Breakthroughs in the basic science of AD has led to new insights into potential therapeutic strategies targeted at the secretases involved in the metabolism of the Alzheimer precursor protein. An immunization approach in which the amyloid-β protein itself was used as the immunizing agent was discontinued after unexpected toxicity occurred. Other areas of investigation with disappointing results such as estrogen replacement therapy and antiinflammatory approaches are discussed. Several other potential therapeutic agents are also reviewed.

Original languageEnglish (US)
Pages (from-to)93-101
Number of pages9
JournalClinical Neuropharmacology
Volume26
Issue number2
DOIs
StatePublished - Mar 2003

Fingerprint

Alzheimer Disease
Drug Therapy
Amyloidogenic Proteins
Amyloid Precursor Protein Secretases
Estrogen Replacement Therapy
Protein Precursors
Cholinesterase Inhibitors
Therapeutics
Publications
Immunization
Anti-Inflammatory Agents

Keywords

  • Alzheimer disease
  • Amyloid-β protein
  • Cholinesterase inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacotherapy for Alzheimer's disease : 2002. / Knopman, David S.

In: Clinical Neuropharmacology, Vol. 26, No. 2, 03.2003, p. 93-101.

Research output: Contribution to journalArticle

@article{5c90375007cb40409890cde307bfd1c8,
title = "Pharmacotherapy for Alzheimer's disease: 2002",
abstract = "The intensity of interest in therapy for Alzheimer's disease (AD) has accelerated with each passing year. The nature of the effects of cholinesterase inhibitors has been refined with the publication of several studies that have examined long-term therapy as well as different aspects of the symptomatology of AD. Breakthroughs in the basic science of AD has led to new insights into potential therapeutic strategies targeted at the secretases involved in the metabolism of the Alzheimer precursor protein. An immunization approach in which the amyloid-β protein itself was used as the immunizing agent was discontinued after unexpected toxicity occurred. Other areas of investigation with disappointing results such as estrogen replacement therapy and antiinflammatory approaches are discussed. Several other potential therapeutic agents are also reviewed.",
keywords = "Alzheimer disease, Amyloid-β protein, Cholinesterase inhibitors",
author = "Knopman, {David S}",
year = "2003",
month = "3",
doi = "10.1097/00002826-200303000-00009",
language = "English (US)",
volume = "26",
pages = "93--101",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Pharmacotherapy for Alzheimer's disease

T2 - 2002

AU - Knopman, David S

PY - 2003/3

Y1 - 2003/3

N2 - The intensity of interest in therapy for Alzheimer's disease (AD) has accelerated with each passing year. The nature of the effects of cholinesterase inhibitors has been refined with the publication of several studies that have examined long-term therapy as well as different aspects of the symptomatology of AD. Breakthroughs in the basic science of AD has led to new insights into potential therapeutic strategies targeted at the secretases involved in the metabolism of the Alzheimer precursor protein. An immunization approach in which the amyloid-β protein itself was used as the immunizing agent was discontinued after unexpected toxicity occurred. Other areas of investigation with disappointing results such as estrogen replacement therapy and antiinflammatory approaches are discussed. Several other potential therapeutic agents are also reviewed.

AB - The intensity of interest in therapy for Alzheimer's disease (AD) has accelerated with each passing year. The nature of the effects of cholinesterase inhibitors has been refined with the publication of several studies that have examined long-term therapy as well as different aspects of the symptomatology of AD. Breakthroughs in the basic science of AD has led to new insights into potential therapeutic strategies targeted at the secretases involved in the metabolism of the Alzheimer precursor protein. An immunization approach in which the amyloid-β protein itself was used as the immunizing agent was discontinued after unexpected toxicity occurred. Other areas of investigation with disappointing results such as estrogen replacement therapy and antiinflammatory approaches are discussed. Several other potential therapeutic agents are also reviewed.

KW - Alzheimer disease

KW - Amyloid-β protein

KW - Cholinesterase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0037349681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037349681&partnerID=8YFLogxK

U2 - 10.1097/00002826-200303000-00009

DO - 10.1097/00002826-200303000-00009

M3 - Article

VL - 26

SP - 93

EP - 101

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 2

ER -